Nanobiotix is trading 10.3% up at $42.26, but the catalyst remains unclear.
- No clearly dated August 17, 2026 company-specific announcement, earnings release, regulatory decision, or analyst action was identified in available coverage.
- Recent reporting focuses on earlier clinical data and valuation momentum, including positive JNJ-1900 results and analyst price-target increases; these developments do not directly explain the August 17 move.
- The broader market is mixed.